Ann: ADVENT-AML clinical trial GMP manufacturing complete, page-6

I agree Bathurst. Seeing it rise recently to 4cents shows there is interest in CHM. I like the pipeline of products being built and so do the directors. I think we have found the floor (touch wood). For me this is great buying opportunity and one of those stocks you need to be patient with. Rewards for patients and investors could be amazing. JC and team seem optimistic . The fly in the ointment is the financial headwinds blowing all biotechs off course. Next 18 months will be exciting. I will continue to buy up stock at these basement prices and let the A team do there work. Fingers crossed we start to see more investors heading back into the health care sector.